California-based AI drug discovery startup Genesis Therapeutics has entered into a research collaboration with Eli Lilly to discover and develop novel therapeutics across a variety of therapeutic areas.
Genesis will receive up to USD 670 million in total consisting of an upfront payment, milestone payments, and R&D funding, with the potential for additional royalties on net sales.
As an upfront payment, Genesis will receive USD 20 million to initially research three targets by leveraging its AI-powered molecular drug discovery platform. Further, Lilly will have the option to nominate two more targets for an additional payment. The collaboration will also leverage the talent and drug discovery expertise of both parties.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.